Pediatric Leukemia and Lymphoma Steering Committee
The Pediatric Leukemia and Lymphoma Steering Committee (PLLSC) was established in 2011. PLLSC members include representatives from the Children's Oncology Group, pediatric and medical oncologists and other specialists, translational scientists, biostatisticians, patient advocates, and NCI staff.
The PLLSC follows a data-driven, transparent process to identify and promote the best science in clinical research for pediatric and adolescent patients with leukemia, lymphoma, and other hematologic malignancies by evaluating and prioritizing phase II and phase III clinical trial concepts.
Roster of Pediatric Leukemia and Lymphoma Steering Committee (PLLSC) members
Robert Arceci, M.D., Ph.D. - Chair; William L. Carroll, M.D. - Vice Chair
Clinical Trial Planning Meetings (CTPM)
The Goal of CTPMs is to:
- identify strategic directions for clinical trials in a specific field
- reach consensus on the most important clinical trials to conduct;
- identify portfolio gaps and emerging scientific opportunities;
- identify innovative trial design opportunities;
- facilitate innovation and collaboration among the broad oncology community active in the specific cancer under study
- COG-ANHL1131: Intergroup Randomized Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or B-Acute Leukemia (B-AL): Rituximab Evaluation in High Risk Patients (NCT01516580)
- COG-ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myeolomonocytic Leukemia (JMML) (NCT01824693)
- COG-ANHL12P1: A Pilot Study of Brentuximab Vedotin and Crizotinib in Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (NCT01979536)
To search all active clinical trials, go to: http://www.cancer.gov/clinicaltrials/search
CCCT Contact: Wolf Lindwasser, Ph.D.